Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YG501
- Development stage
- Preclinical
- Lead developer
- Wingor Biotechnology
- Modality
- Cell Therapies
01
Overview
YG501 is an investigational immune cell therapy consisting of invariant Natural Killer T (iNKT) cells, also referred to as W-iNKT, developed by Wingor Biotechnology. It is designed for the treatment of gastrointestinal tumors, including esophageal, gastric, and colorectal cancers. iNKT cells represent a unique lineage of T cells that share properties of both T cells and natural killer (NK) cells, allowing them to mount potent anti-tumor immune responses. YG501 is currently in preclinical development, with investigator-initiated clinical trials (IIT) underway in China to evaluate its safety and efficacy as an adjuvant therapy.
- Other names
- W-iNKTW-iNKT cell therapyW-iNKT cellsW-iNKT therapy
Beyond the preview
Go deeper on YG501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YG501.